pALD-AAV System

pALD-AAV System Overview

Recombinant AAV (rAAV) manufacturing is composed of four main components which include a rep/cap plasmid, a helper plasmid, a transgene plasmid, and a viral packaging cell line. Triple transfection of the three plasmids into HEK293 cells is the most frequently used rAAV production method.

Benefits of pALD-AAV

  • Royalty free, including for commercial products
  • Kanamycin resistance
  • Consistent, reliable supply
  • Immediately available at research grade
pALD AAV System Process Illustration

Rep/Cap Plasmids

Our rep/cap plasmids provide the appropriate packaging functions for AAV-based gene therapeutics.



Learn more

Custom Manufacturing

Order custom products with different buffers, concentrations, and more.



Get Started

Standardized Plasmids for Viral Vector Production | James Brown, Ph.D.

What are the advantages of using standardized plasmids? As James Brown explains, large scale production of these plasmids for gene therapy offer researchers the opportunity to lower costs on their projects while working with shorter timelines.


Related News

In the News: AavantiBio and Aldevron Announce Strategic Partnership to Develop Next Generation Gene Therapies for Rare Genetic Diseases

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, a global leader in the...

In the News: Aruvant Partners with Aldevron to Provide Key Plasmid Raw Materials Used to Manufacture Pipeline Products

Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Aldevron, the leading provider of high-quality...

In the News: Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline

Moderna, Inc. (Nasdaq:MRNA), and Aldevron have announced their expanded collaboration in support of the Moderna COVID-19 Vaccine and additional...

Related Blog Posts

The Pivotal Role of Plasmid DNA

Plasmid DNA has historically been key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of...

Plasmid DNA Insights: Expanded Focus on CMC in Gene & Cell Therapy Development

Aldevron recently hosted a webinar through Endpoints news titled: Plasmid DNA Insights: Expanded Focus on CMC in Gene and Cell Therapy Development....

DNA Plasmids for the Genetic Engineering of Clinical-Grade T Cells

Our inaugural presentation for the Breakthrough Speaker Series is Dr. Laurence Cooper, on behalf of ZioPharm Oncology, presenting "DNA Plasmids for...